Small cap News

Intelligent Bio Solutions announced a partnership with Syrma Johari Medtech, a medical device engineering and manufacturing organization based in India.

The company disclosed the terms and timeline of an SPV arrangement tied to its Oz-V development program.

Vanda is expected to launch NEREUS, a motion-sickness treatment aimed at preventing vomiting, in the coming months.

Shares rebounded sharply after the company disclosed fresh capital-raising plans following a steep selloff.

Innodata operates as an AI enabler rather than a core AI platform, but is delivering strong revenue and EBITDA growth and guiding for 45%+ organic growth in 2025.

Pentagon backing for more AI-powered data solutions and a part of the Golden Dome contract has helped Sidus Space see a surge.

The company’s board of directors has approved a share buyback program of up to $125 million.

The company said that U.S. Patent No. 12,492,179 extends the protection for its pipeline of potentially neuroplastogenic, non-hallucinogenic molecules.

Vanda’s shares have surged since mid-November ahead of a pivotal FDA decision on tradipitant for motion sickness, a binary event that could unlock a new market and drive further upside, with additional regulatory catalysts ahead.

The platform, TMG Social, offers brands a range of options to enable their social commerce efforts, including shoppable posts, livestream shopping, and more.

The deal positions Medirom at the center of Japan’s push to deploy human-verification infrastructure as AI adoption accelerates.

The stock pullback reflects renewed uncertainty around regulatory and legal hurdles tied to Sable’s main producing asset.

Nvidia shares were up nearly 2% in Friday’s midday trade after the company entered into a non-exclusive licensing agreement with Groq for its inference technology.

Arcadia and Roosevelt had entered into a business combination agreement in December 2024 in the form of an all-stock transaction.

The stocks were tracked during the shortened Christmas Eve session across healthcare, consumer, and banking.

Regulatory thaw, political backing, and late-stage data are propelling psychedelic drugmakers into the biotech spotlight — with Compass Pathways and Mind Medicine leading the charge.

The drug was approved for use in adults and children aged two years and older.

Repare stated that Gilead has agreed to acquire polymerase theta (Polθ) ATPase inhibitor, RP-3467, for a total consideration of $30 million.

The stock continued to face pressure as investors weighed the risks and uncertainty surrounding the company’s proposed pivot.

Novo Nordisk shares were up more than 9% in Tuesday’s midday session after the company said that the U.S. FDA has approved its Wegovy pill for weight loss.

Shares fell as investors flagged limited commercial impact from the pediatric approval and questioned the timing of the announcement during thin holiday trading.

Following the Trump administration's executive order issued last week to sharpen the focus of the U.S. space policy, Starfighters Space stated that it will advance its commercial and government mission activities.

Quantum computing stocks remain volatile and speculative, but rising institutional validation and sustained retail optimism suggest the sector’s rally still has legs.

The company stated that these new patents enhance its existing technologies, such as Sumerian Crypto Anchors, DataScore, and DataValue AI agents.

Nike shares were down more than 10% in Friday’s midday session after CEO Elliott Hill stated that the company is still facing a “longer road to a healthier business” in China.

Shares rose on a combination of defense-related developments, recent launch activity and broader strength across space stocks.

Geopolitical tensions lifted critical metal stocks as U.S. reshoring efforts, government backing, and supply fears drove gains.

The two companies are joining forces in a $2.5 billion deal to bring their offerings under one roof, boosting revenue and profit as growth tapers.

Massive gains in a little-known Indian semiconductor firm were driven by hype and a limited float, overshadowing concerns about losses, disclosures, and regulatory scrutiny.

Oracle shares were down over 5% in Wednesday’s midday session after Blue Owl Capital reportedly withdrew from a $10 billion investment in the company’s new facility in Saline Township, Michigan.

The FDA delayed its decision on the dry eye drug Reproxalap to March 2026 without raising new issues, while review and labeling discussions continued.

Tesla shares were up nearly 4% in Monday’s midday trade after CEO Elon Musk stated in a post on Sunday that the EV giant had begun fully autonomous testing of Robotaxis in Austin.

Milestone stated in its announcement that the approval of Cardamyst opens up an addressable market of more than two million Americans who suffer from PSVT.

The Children’s Place was once the go-to place for parents to shop for their kids, but it has lost its old charm, though a regrowth strategy is now in the works.

In a post on X, Nano Labs CEO Jack Kong said roughly 400,000 Bitcoin mining machines went offline in Xinjiang, cutting 100 EH/s from the global network.

Broadcom shares were down more than 11% in Friday’s midday session after CEO Hock Tan’s $73 billion AI backlog order statement failed to impress Wall Street.

The proposal would see a new chair appointed first, followed by the selection of a new chief executive, replacing Sue Nabi after a period of weak operating performance, according to a report by The Financial Times.

Jiuzi announced that the $12 million private placement plan had been expanded to $1 billion, marking an 83-fold increase in the financing scheme.

The FDA’s designation broadens Atossa’s development pathway in DMD and could make the program eligible for a Priority Review Voucher.

Black Titan Corporation plans to develop a strategic framework to guide its future entry into digital assets.

According to Grayscale, the Trust is currently in charge of about $10.8 million in assets.

The company said the accumulation was made through Bitcoin mining and strategic purchases.

The company's stem cell drug burixafor helped nearly 90% of patients meet the Phase 2 goal.

A majority stake and eventual buyout of a company with access to Israel’s defense supply chain position Nukkleus to be a broad-based firm focused on defense AI news and the development of defense systems.

Paranovus reported a return to profitability, margin expansion, and strong contributions from its U.S. e-commerce and TikTok-focused units.

The company said it has reduced its flexible-term debt by $1.5 million, lowering total debt to $7.9 million from $9.4 million.

The plan, described as a “moonshot” structure, is designed to align leadership and early investors’ pay with long-term shareholder value.

The Tel Aviv, Israel-based company said this agreement is expected to deliver “meaningful” six-figure revenue with a strong growth potential.

DMD patients may soon gain access to a therapy that not only targets muscle decline but also tackles heart complications — the leading cause of death in this rare genetic disorder.

Here’s a look at what drove the moves and which meme stocks investors might watch for 2026.